Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)

NCT02332512 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

417

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Apatinib
DRUG: Placebo

Sponsor

Jiangsu HengRui Medicine Co., Ltd.